Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities by Affer, M. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2011, Article ID 798592, 25 pages
doi:10.1155/2011/798592
Research Article
GeneExpression Differences between Enriched Normaland
ChronicMyelogenous Leukemia QuiescentStem/ProgenitorCells
andCorrelations withBiological Abnormalities
M. Affer,1 S.Dao,2 C.Liu,2 A.B.Olshen,3 Q.Mo,4 A.Viale,5 C.L.Lambek,2 T. G. Marr,6
and B.D. Clarkson2
1Mayo Clinic, Scottsdale, AZ 85259, USA
2Molecular Pharmacology & Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York,
NY 10065, USA
3Department of Epidemiology-Biostatistics UCSF, San Francisco, CA 94107, USA
4Department of Epidemiology-Biostatistics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York,
NY 10065, USA
5Genomics Core Laboratory, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
6Hiberna Corporation, 1941 Pearl Street, Suite 200, Boulder, CO 80302, USA
Correspondence should be addressed to M. Aﬀer, aﬀer.maurizio@mayo.edu
Received 28 July 2010; Revised 17 November 2010; Accepted 7 December 2010
Academic Editor: Aurelio Lorico
Copyright © 2011 M. Aﬀer et al.Thisisanopenaccessarticledistributed undertheCreative CommonsAttribution License,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In comparing gene expression of normal and CML CD34+ quiescent (G0) cell, 292 genes were downregulated and 192 genes
upregulated in the CML/G0 Cells. The diﬀerentially expressed genes were grouped according to their reported functions, and
correlations were sought with biological diﬀerences previously observed between the same groups. The most relevant ﬁndings
include the following. (i) CML G0 cells are in a more advanced stage of development and more poised to proliferate than normal
G0cells.(ii)WhenCMLG0cellsarestimulatedtoproliferate,theydiﬀerentiate andmaturemorerapidlythannormalcounterpart.
(iii) Whereas normal G0 cells form only granulocyte/monocyte colonies when stimulated by cytokines, CML G0 cells form a
combination of the above and erythroid clusters and colonies. (iv) Prominin-1 is the gene most downregulated in CML G0 cells,
and this appears to be associated with the spontaneous formationof erythroid colonies by CML progenitors without EPO.
1.Introduction
Chronic Myelogenous Leukemia (CML) represents about
15–20% ofall cases of adult leukemia in western populations
[1]. CML is a clonal myeloproliferative disease characterized
b yt h ep r e s e n c ei n>95% of patients of the t(9;22)(q34;11)
translocation known as the Philadelphia Chromosome [2].
This translocation causes expression of the BCR-ABL fusion
protein,atyrosine kinasewith constitutivelyincreased kinase
activity[3]whichisthoughttobenecessary andsuﬃcientfor
the initiation of CML [4].
The development of small molecule tyrosine kinase
inhibitors (TKIs), such as Imatinib Mesylate, which inhibits
the increased BCR-ABL tyrosine kinase activity, have dra-
matically improved the prognosis of patients with CML
[5, 6]. Imatinib Mesylate induces complete hematologic
remissions and cytogenetic responses in the majority of
patients in chronic phase CML, but the response in more
advanced stages is usually only partial and less durable.
About 4-5% of patients per year develop resistance to
Imatinib either because of Bcr-Abl gene ampliﬁcation or
more commonly point mutations in Bcr-Abl [7, 8]. If
Imatinib is discontinued because of toxicityor other reasons,
the majority of patients relapse fairly promptly [9]. One
hypothesis that could explain the customary relapses after
s t o p p i n gt h e r a p yi st h a tT K I sa n dc o n v e n t i o n a lc y t o t o x i c
drugs therapies are unable to eliminate all BCR-ABL positive
cells, presumably sparing a relatively small number of
leukemic early progenitors and stem cells that are quiescent
and are not killed by the inhibitors or other drugs at2 Journal of Oncology
clinicallytolerableconcentrations[10].These cellsconstitute
a reservoir of BCR/ABL positive cells capable of functioning
as leukemic stem cells or “limited stem cells” [11]. If for any
reason a patienthas tostoptherapy,these cells havesuﬃcient
self-renewal ability to recreate the disease by reconstituting
the stem cell population and also enhancing the probability
that the leukemic cells will develop resistance to the drugs,
leaving bone marrow transplantation as the only option for
survival.
In order to search for critical diﬀerences in biochemical
pathwaysandregulatorynetworksbetweenCMLandnormal
quiescent progenitors and stem cells that might ultimately
serve as selective targets, we decided to compare the gene
expression proﬁles of the normal and CML quiescent cell
fractions. As a strategy to enrich for these quiescent cells,
we isolated CD34+ cells by positive selection from the
mononuclear cells of normal bone marrow and CML blood
samples and then separated the CD34+ cells into G0 and
G1/S/G2/M fractions by ﬂow cytometry. We found 1, 204
genes signiﬁcantly upregulated and 1, 133 downregulated
in CML-G0 cells compared to normal G0 cells (resp., 3.1%
and 2.9% of the genes represented on the Aﬀymetrix chip),
thereby permitting us to compare gene expression proﬁles in
highly enriched normal and leukemic quiescent progenitors
and stem cells.
2.MaterialandMethods
2.1. Patients and Bone Marrow Controls. A total number of
eight patientsdiagnosed with Ph+ CML (three in accelerated
phase and ﬁve in chronic phase) were used in this study. The
CML samples were all obtained from patients hospitalized at
the Memorial Hospital during the period 1990–2006.
The bone marrow samples were purchased from Cam-
brex (Cambrex Bio Science Rockland, Inc., Rockland, Maine
04841, USA).
2.2. CD34+ Cells Enrichment. Mononuclear cells were iso-
latedonaFicollgradient(Ficoll-PaquePLUS,GEHealthcare,
Cat#17-1440-03)from totalnucleated cellsofbone marrows
of four healthy donorsand peripheral blood of eight patients
with untreated Ph+ CML (ﬁve in chronic and three in
early accelerated phase with 8.5–18% blasts in the peripheral
blood). In the case of the patient samples, total cells after
Ficoll were frozen in liquid nitrogen in RPMI plus 10%
dimethyl sulfoxide and 10% fetal calf serum and stored until
selection. The normal bone marrows were instead processed
the same day of their arrival.
CD34+ cells were positively selected using a midiMACS
immunomagnetic separation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany, CD34 progenitor Cell Isolation Kit,
Cat# 130-0460701) after one round of puriﬁcation, the
recovered cells were passed through another round of
puriﬁcation using a second column. This way the purity of
the CD34+ recovered cells was 96–100% as assessed by ﬂow
cytometry. For the statistics about the starting number of
cells from each sample and the CD34 recovered fraction, see
Table 1.
2.3.Hoechst33342and Pyronin YStaining forG0Cells Enrich-
ment. CD34+ cells were resuspended at a concentration of
two million per 0.5ml of staining buﬀer (SB: HBSS without
NaHCo3, 10mM Hepes, 1% BSA, 2% Fetal Calf Serum)
plus Hoechst 33342 (bisBenzimide H 33342, Cat# B2261,
Sigma, St. Louis, Missouri, USA) at a ﬁnal concentration of
20nM/ml and incubated for 45  in a water bath at 370C.
After washing once with SB plus 10% Hoechst, the cells were
resuspended in 0.5ml of SB plus Pyronin Y (Cat# P9172,
Sigma)at a ﬁnal concentrationof1μg/ml and keptina water
bathat37◦Cf or20  , washed onceand resuspended in 1ml of
SB.
After being stained, the cells were sorted using a MoFlo
ﬂow cytometer (DakoCytomation, Dako Colorado, Inc. Fort
Collins, Colorado, USA) applying a gate in the region of
logarithmic ﬂuorescence intensity of 1000+ / −100 for both
Pyronin Y (FL3) and Hoechst (FL7). An example of the
gating strategies is shown in Figure 1(a).
2.4. BrdU Staining. Approximately 50,000 cells from the
CML/G0 and CD34+/G1/S/G2/M fractions were analyzed
for BrdU incorporation using a Roche kit (Cat# 11 296
736 001). Cells were pulsed with BrdU for an hour in
complete growth medium, ﬁxed with Ethanol, stained with a
mouse anti-BrdU monoclonal antibody, and then incubated
with an anti-mouse-Ig ﬂuorescein conjugated antibody.
Cells that incorporated BrdU were then counted using an
immunoﬂuorescence microscope Figure 1(b).
2.5. RNA Isolation, Labeling, Hybridization, and Microarray.
Total RNA was isolated from each group of cells sorted
from the G0 control fraction (BM) or CML sample using
TRIzol reagent (Cat#15596-026,Invitrogen Corp., Carlsbad,
CA, USA). Quality of RNA was ensured before labeling by
analyzing 5pg ofeach individual sample using the RNA6000
picoAssay and a Bioanalyzer 2100 (Agilent Technologies,
Inc., Santa Clara, CA, USA). Samples with a RNA Integrity
Number (RIN) greater than 7.0 were considered suitable for
labeling. For each sample meeting this standard, 20ng of
total its RNA were labeled using the GeneChip two-cycle
target labeling kit (Aﬀymetrix, Inc., Santa Clara, CA, USA).
Ten micrograms of labeled and fragmented cRNA were then
individually hybridized to the Human Genome U133 plus
2.0 array (Aﬀymetrix) at 45◦C for 16h. Automated washing
and staining were performed using the Aﬀymetrix Fluidics
Station 400 according to the manufacturer’s protocols.
Finally, chips were scanned with a high-numerical Aperture
and ﬂying objective (FOL) lens in the GS3000 scanner
(Aﬀymetrix). In summary, from each sample (CML or Bone
Marrow), we extracted RNA and performed a separate gene
expression proﬁle and the changes in gene expression were
derived from the statistical analysis in which we compared
CML samples (eight independent gene expression data)
Versus Bone marrow (ﬁve independent gene expression
data).
2.6. Statistical Analysis. T h em i c r o a r r a yd a t aw e r eq u a n t i l e -
normalized, and the gene expression values were estimatedJournal of Oncology 3
Table 1:Numbers ofG0andG1/S/G2/M cells recovered from highlyenriched normalandCML CD34+ population.In theupper part ofthe
table are shown the data showing the recovery of cells from normal bone marrows and in the lower part the recovery of cells from the CML
patients. In bold is the average recovery of each fraction relative to the CD34+ starting population. The last column shows the percentage
of blasts from each patient at the moment of sample collection, and the asteriks indicate the patients in accelerated phase (more than 5% of
blasts). Cells recovered from BM #2 were not used due to the insuﬃcientnumber of cells recovered. Legend: starting CD34+ cells in millions
(S-CD34+), CD34+ G1/S/G2/M cells recovered (R-CD34+ G1/S/G2/M), CD34+ G1/S/G2/M cells recovered as % of starting CD34+ cells
(%G1/S/G2/M), CD34+ G0 cells recovered (R-G0), and CD34+ G0 cells recovered as % of starting CD34+ cells (% G0).
Normal BM S-CD34+ R-G1/S/G2/M %G1/S/G2/M R-G0 %G0 % blasts
1 2.55 400,000 15.3 50,000 1.96 —
2 0.5 64,000 12.8 19,400 3.9 —
3 5.85 1,000,000 17.1 400,000 6.84 —
4 2.8 370,000 13.2 73,000 2.56 —
5 3.6 1,170.00 32 238,000 6.6 —
Mean = 3.06% Mean = 18.0% Mean = 4.3%
CML patient S-CD34+ R-G1/S/G2/M %G1/S/G2/M R-G0 %G0 % Blasts
1 6 580,000 9.6 100,000 1.6 2%
2 3.5 387,000 11 123,000 3.51 1%
3 0.9 230,000 25.5 42,000 4.6 <3%
4 1.7 320,000 18.8 74,800 4.4 3%
5 4.25 310,000 7.29 150,000 3.52 1%
6 4.59 300,000 6.53 150,000 3.26 ∗18%
7 0.85 158,000 18.5 13,500 1.58 ∗14%
8 3.45 719,000 20.8 68,700 1.99 ∗8.5%
Mean = 3.15% Mean = 14.7% Mean = 3.2%
using the RMA method [12]. A linear regression model was
used to model the gene expression values, in which a batch
factor was added to the model to account for potential batch
eﬀect since arrays were run in two distinct batches two years
apart. Diﬀerences between the G0 gene expression values of
CML and normal samples were tested using the moderated
t-statistics. Storey’s q-value that control false discovery rate
was used to correct for multiple hypothesis testing [13]. A
q-value less than 0.1 was considered statistically signiﬁcant.
The microarray data have been deposited on the GEO
public repository (http://www.ncbi.nlm.nih.gov/geo/)u n d e r
accession no. 15881331.
2.7. RT-qPCR. RT-qPCR assay was used to determine the
level of expression of the genes we found up and downreg-
ulated on the microarray.
We used the IScript One-Step RT-PCR Kit with SYBR
Green (Cat# 170-8892, Biorad, Hercules, CA, USA) with the
following conditions: 101 @5 0 ◦C, 51 @9 5 ◦C, 101 @9 5 ◦C,
and 301 @6 0 ◦Cu s i n g1 n go fR N Af o re a c hr e a c t i o na s
a template. All samples were run in quadruplicate on an
ABI9700platform(PerkinElmer/AppliedBiosystems,Foster
City, CA, USA).
The relative expression of each gene was calculated
using the ΔΔct method using GAPDH as a reference gene.
Forward and reverse primers were designed in diﬀerent
exons, in order to avoid DNA contribution to our ﬁnal
PCR product, using Primer 3 software (available on line at:
http://frodo.wi.mit.edu/).
For the sequence of the primers used, see Table 1 in Sup-
plementary Material available online at doi:10.1155/2011/
798592.
2.8. Colony Assays and Cytokines. T h r e eo rf o u rh u n d r e d
total CD34+ cells or CD34+ G0 and G1/S/G2/M enriched
cells per plate were assayed for colony growth in 1.3%
methylcellulose as described in detail previously [14].The
cloning eﬃciency (C.E.) values are the average of 4 plates
counted for each bar shown. Unless otherwise stated, either
single (100ng/ml) or three early acting cytokines: KL, FL,
TPO (50ng/ml each) with orwithout additional cytokinesas
noted:G-CSF,GM-CSF(10ng/mleach),IL-3,IL-6(20ng/ml
e a c h ) ,a n dE P O1I U / m lw e r ea d d e d± the drugs shown to
the cultures to stimulate or inhibit colony growth. Unless
otherwise noted, 3 cytokines refer to KL+FL+TPO and 5, 6,
7, or 8 cytokines refer to KL + FL + TPO + G-CSF + GM-
CSF ± IL-3 ± IL-6 ± EPO in that orderat the concentrations
indicated above. Quadruplicate plates of each sample were
c o u n t e da td a y s1 4o r1 5u s i n ga ni n v e r t e dm i c r o s c o p e
includingestimatesofcolonylineageandsize.Astandardized
scale and colorcode for estimating colony size has long been
used in our laboratory which has been veriﬁed by plucking
single large and multiple smaller (pooled) colonies and
hemocytometer counts of the numbers of cells contained in
the diﬀerent sized colonies. GFU-GM: tiny < 40 cells, small
40–100, medium 1000–10,000, large 10,000–40,000, X-large
40,000–100,000, XX-large > 100,000 cells; CFU-E and BFU-
Ea n dm i x e d :t i n y< 50–5000, medium 5000–50,000, large4 Journal of Oncology
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Figure 1: (a) Flow chart of the separation and sorting of the cells used for generating the microarray data. Cells from healthy bone marrows
and CML patients went through a round of Percoll (to separate the mononuclear cells) and Ficoll (to eliminate dead cells). Highly enriched
CD34+ cells were isolated from the mononuclear cells by two rounds of immunomagnetic separation using a Myltenyi kit, and the CD34+
cells were then stained it with Hoechst and Pyronin and sorted by FACS. The G0 cells are in the region of low ﬂuorescence intensity for both
dyes, and the G1/S/G2/M cells have a high level of Hoechst and PyroninY. (b) BrdU staining of a CML CD34+/G1/S/G2/M and CD34+/G0
quiescent fraction. To further validate our separation procedure, we pulsed labeled CML CD34+/G0 and G1/S/G2/M cells with BrdU. After
1 hour’s exposure, 22% of the cells from the CML cycling fraction were labeled with BrdU compared to 0.68% of the quiescent cells. The
BrdU positive cells are ﬂuorescent (green) while the blue are Dapi stained nuclei without BrdU incorporation. Left panel: CML G1/S/G2/M
cells. Right panel: CML G0 cells. (c) Gene expression array data validation by qPCR. To conﬁrm the diﬀerences in gene expression found
by our microarray data analysis between the CML/G0 and BM/G0, we performed an RT-qPCR on nine up- and ﬁve downregulated genes.
Thirteen out of fourteen genes (the exception being CPI-17) have been conﬁrmed to be up-, or downregulated by this secondtechnique. For
each sample,we ranfour reactions for each gene andthe averagevaluehas been used forthe calculationofrelative expressionusing theΔΔct
method and GAPDH as a calibrator. y-axis: gene expression fold change: CML relative to bone marrow. x-axis: gene tested by RT-qPCR.Journal of Oncology 5
50,000–105,X - l a r g e1 0 5–5×105,X X - l a r g e> 5×105 cells. G-
CSF, GM-CSF, and IL-3 were obtained as gifts from Kirin
Brewery Co., Gunma, Japan and KL (Kit ligand or SCF, Stem
Cell Factor), FL (Flt3 ligand), TPO (Thrombopoietin), IL-
6, and EPO (Erythropoietin) were purchased from R & D
systems, Inc. CD 133/2 APC (293 C3) was purchased from
Miltenyi Biotech, Gladback, Germany. Cord Blood samples
were obtained from the New York Blood Center as samples
judged too small for clinical use; Three or 4 samples were
pooled for our studies.
3.Results
3.1. Custom. Defrosted mononuclear peripheral blood cells
from eight CML patient samples or ﬁve fresh normal bone
marrows were individually used to isolate the CD34+ frac-
tion using the midiMACS immunomagnetic separation Kit
from Miltenyi (see Material and Methods) with a percentage
of purity of recovered cells varying between 95–100%.
CD34+ cells from each samples were subsequently
stained with Hoechst 33342 and Pyronin Y and sorted
individually according to their dye content (Figure 1(a))
[15]. The region chosen for sorting the quiescent fraction
(G0) allowed us to avoid collecting dead cells and cross-
contamination with cycling cells.
We also sorted the proliferating fraction (G1/S/G2/M),
but due to its high heterogeneity, we did not conduct a
detailed analysis on this fraction for comparison with the
CD34+/G0 cells.
3.2. Statistics of Recovered Cells. Table 1 summarizes the
numbers and percentage of CD34+/G0 cells and CD34+
/G1/S/G2/M recovered from each patient and normal bone
marrow.
After Percoll and Ficol separation of total blood cells
from normal bone marrow or CML blood on average22% of
normal and 11% of CML mononuclear cells were recovered.
After passing the MNCs twice on Miltenyi columns for
positive selection of CD34+ cells, 3.06% of normal and
3.15% of CML highly enriched CD34+ cells were obtained
from the MNC fractions. Due to the low quality of RNA
recovered, one BM sample (#2) was not used to generate
microarray data.
TheCD34+cellswerefurtherseparatedintoproliferating
(G1/S/G2/M)andquiescent(G0)fractionsbyﬂowcytometer
using Hoechst and Pyronin y staining.
After sorting, themean and rangeofrecoveries ofnormal
and CML CD34+/G1/S/G2/M were 18% and 14.7%, respec-
tively, while the recoveries of normal and CML CD34+/G0
cells were 4.3% and 3.05%, respectively, or an average of
0.016 and 0.013%, respectively, of the total normal and CML
starting cell populations.
3.3. Quiescent or Proliferative Status of G0 and G1/S/G2/M
Cells. CD34+/G0 and G1/S/G2/M cells were pulse labeled
with BrdU. An average of 27% (22–32%) of unstimulated
CML CD34+ G1/S/G2/M cells incorporated BrdU after an
incubation period of one hour while less than 1% of CML or
normal CD34+G0cellsincorporatedBrdUwithoutcytokine
stimulation immediately after separation. Figure 1(b) shows
representative pictures of CML CD34+ G1/S/G2/M and G0
cells immediately after separation after 1-hour incubation
with BrdU. The few G0 cells that incorporated BrdU all
showed punctated nuclear labeling indicating an early stage
of DNA synthesis while the G1/S/G2/M cells had varied
nuclear staining patterns indicating diﬀerent stages of DNA
synthesis.
Withoutcytokines,theviabilityofbothnormalandCML
G0 and G1/S/G2/M cells declines rapidly and few viable
labeled or unlabeled cells remain after 2-3 days and almost
none after 4-5 days.Viability was estimated by the fraction of
intact cells excluding trypan blue. However in the presence
of 6 or 7 cytokines (KL + FL + TPO, each 50ng/ml, + G-
CSF + GM-CSF + IL-3 ± IL-6, each 10ng (ml), viability
remains excellent (95–100%) and the majority of both
normal and CML total CD34+ cells and G0 and G1/S/G2/M
cells are induced to proliferate rapidly in liquid culture with
average doubling times of ∼30 hours. Continuous exposure
to BrdU (5μm) is toxic to both proliferating normal and
CML cells, and viability declines rapidly after 2 days so
results comparing incorporation of BrdU during continuous
exposure of cytokine stimulated G0 cells is limited to the
ﬁrst 48 hours. With stimulation by 7 cytokines, 92% and
94% of CML G0 cells incorporated BrdU during continuous
exposure for 24 and 48 hours, respectively, (average of 3
experiments) while the corresponding 24 and 48 values
for normal G0 cells were 8% and 72%, respectively. These
experiments suggest that the majority of both normal and
CML CD34+G0 and G1/S/G2/M cells remain viable and can
be stimulated to proliferate with 7 cytokines, but that the
CML/G0 cells are more poised than the normal G0 cells to
begin proliferating.
3.4. Microarray Data Validation. To validate the robustness
of our microarray data, we performed quantitative real-time
PCR(qPCR)independentlyoneachoffourCMLCD34+/G0
and two normal bone marrow CD34+/G0 samples that were
diﬀerent from the ones used to generate the microarray data.
On each sample, we tested theexpression ofall thegenesrep-
resented in Figure 1(c), averaged the results obtained either
from the four CML samples or two BM and then calculated
the resulting fold change in expression foreach genebetween
the two groups. Since the amount of RNA recovered after
the sorting was very limited, we performed a single-step RT-
qPCR using the ΔΔct method (the primers used are listed
in Table 1, in Supplementary Material available online at
doi:10.1155/2011/798592). This way, we were able to use as
little as 0.1ng per reaction enabling us to do four replicates
per gene tested. We found that out of fourteen genes tested,
which were diﬀerentially expressed between the normal and
CML/G0 by the microarray, thirteen were conﬁrmed by
qPCR (Figure 1(c)).
3.5. Signature of CML and Normal Bone Marrow CD34+/G0
Cells. Using a q value of less than 0.05 as a threshold,6 Journal of Oncology
we found 1,204 genes signiﬁcantly upregulated and 1,133
downregulated in CML/G0 compared to normal BM/G0
cells (for a complete list of the genes see Supplementary
Material available online at doi:10.1155/2011/798592). As
an additional criterion for selecting the genes signiﬁcantly
diﬀerentially expressed, we considered in the analysis only
those with diﬀerences in expression higher than three folds.
This resulted in 292 down- and 192 upregulated genes
to be considered. Using this as a starting point, we later
extendedtheanalysistolookforgenesthatcouldcorroborate
our initial tentative conclusions, but in this second step,
we considered also genes that had at least a two-fold
diﬀerence and more than one set of probes changed. We
havegrouped thegenes accordingt otheirr eport edf unctions
and discussed the possible signiﬁcance of the most relevant
ﬁndings regarding diﬀerences between normal and CML
CD34+/G0 cells.
3.6. Cell Cycle/DNA Replication Related Genes. In the genes
linked to cell cycle regulation, we found an almost equal
number of them diﬀerentially expressed characterizing
CML/G0 cells as nonproliferative when compared to normal
G0 cells, (e.g., upregulation of MTSS and downregulation
of CDC14B), and as proliferative via upregulation of CDC6
and cyclin B2. The most striking diﬀerence is in the number
of genes upregulated in the CML/G0 cells that are either
involved in DNA replication (TOPO2a, RRM2, GINS1 and
2) or are part of the mitotic spindle machinery (MAP9,
CETN3, ANLN, DLG7). This subset of CML cells seems to
be in a nonproliferative state but essentially ready to enter
into the cell cycle upon stimulation, having the machinery
for cell division and DNA replication expressed and ready to
work. This conclusion is compatible with ﬁndings reached
independently by another group [16], showing that CML
cells are much more easily triggered into cell cycle than their
normal counterparts.
3.7. Stem Cells and Hematopoietic Stem Cells Markers.
Among the most signiﬁcantly diﬀerentially expressed genes
that we found between the CML and normal quiescent cells,
many of these genes have been reported to be associated
with stem cells. The ﬁrst three genes belonging to this
group are Prominin-1 (CD133) [17], ID1 [18], and FLT3
[19]. A second group includes genes that have been found
overexpressed in both of two independent studies that have
analyzed hematopoietic stem/progenitorcell transcriptomes,
HLF, RBPMS (HERMES), GATA3, TNFSF10 (TRAIL), and
CRHBP [20, 21].
The third group includes: CD110/MPL, GBP2, SPTBN1,
A R G 2 ,B I R C 3 ,C R H B P ,H L A - E ,H O X A 3 ,H O X B 6 ,S P I N K 2 ,
NRIP1, PRKCH, RAPGEF2, and TLOC1, all genes that
are overexpressed in HSC-enriched populations of bone
marrow/cord blood and mobilized peripheral blood cells
[20].
Last but not least, we found as diﬀerentially expressed
MSI2 (Musashi-2), another well-known stem cell marker
[22], HES-1 a hematopoietic stem cell marker [22]a n dI L 7 ,
that is, expressed in human adipose-derived stem cells [23].
All these genes are overexpressed in hematopoietic
stem/progenitor cells compared to more diﬀerentiated ones,
but in our microarray, all of them are downregulated in
the CML/G0 fraction compared to the normal/G0 fraction.
This provides additional evidence that with the methods
employed, we are indeed enriching for quiescent hematopoi-
etic stem cells and early progenitors in normal bone marrow
but when we apply the same technique to enriching CML
quiescent stem and progenitor cells, the latter are in a
more advanced stage of diﬀerentiation. Because the CML
G0 cells were enriched from the blood of patients with
highly elevated WBC counts while the normal G0 cells
were enriched from the bone marrow, this might oﬀer a
partial explanation. However, since previous labeling studies
conducted in vivo in CML patients with massive myeloid
e x p a n s i o nh a v es h o w nt h e r ei sc o n t i n u o u st r a ﬃcking and
exchange of early progenitors as well as maturing cells
between the bone marrow, spleen, and blood and in whom
the diﬀerential counts and proliferative kinetics of the bone
marrow and circulating cells were very similar [24], it is
more likely that the gene expression results accurately reﬂect
the average results of the entire CML/G0 subpopulation
[25].
Another element that supports our conclusion that the
CML/G0 cells are more diﬀerentiated than the normal G0
cells is that six genes that belong to the Polycomb Repressive
Complex 1 (PRC1), respectively, SCML1, PHF1, PCGF3,
CBX7, L3MBT1, and 4, and one (EPC2) belonging to the
PRC2 group, are downregulated in the CML/G0 fraction
(all of them apart from SCML1, with a diﬀerence in terms
of relative gene expression under the twofold level, so they
are not listed in Table 1). The PRC1 and PRC2 complexes
belong to the groups of epigenetic regulators and act as
gene expression repressors. Both complexes are involved in
the maintenance of adult and embryonic stem cells [26].
Downregulation of genes belonging to these two groups in
the CML/G0 fraction reinforce the idea that the bulk of
quiescent CML cells belong to a more diﬀerentiated state
than the normal counterpart, as also proposed for blastic
phase CML cells in a previous paper by Jamieson [27].
3.8. The Majority of the Quiescent CML Cells Overexpress
Genes Belonging to the Megakaryocyte-Erythroid (M/E) Lin-
eages. Another series of genes diﬀerentially expressed in the
CML/G0fraction enabledustolocalizemore precisely where
the predominant myeloid expansion takes place.CML G0
cells express a series of megakaryocytic (NFE2, TESC and
CD41)and erythrocyte markers (CD36,KLF1,TFR2,ANK1,
and XK and four diﬀerent hemoglobin chains (HBB HBQ1
HBD, and HBG1) plus GATA1, a gene whose expression
is linked to hematopoietic cell diﬀerentiation [28]. The
overexpression of GATA-1 is of particular interest since
Graf has shown that if GATA-1 is expressed in myeloid
cell lines, the cells’ phenotype is completely changed to
erythroid, probably due to inactivation of the myeloid
regulator PU-1 by GATA-1 [29]. An unexpected ﬁnding,
in view of the more prominent hyperproliferation of
megakaryocytic than erythroid cells in CML, is that SMAD7,Journal of Oncology 7
whose expression promotes megakaryocytic over erythroid
diﬀerentiation [30], is downregulated in CML/G0 cells.
On the other hand, two key genes promoting lymphoid
diﬀerentiation (BCL6 and GATA3) are downregulated and
a gene expressed in neutrophils (NCF4) is upregulated, as
might be expected. These data might be explained by the fact
that CML G0 cells are neoplastic cells and therefore exhibit
a common cancer-associated characteristic variously termed
“lineage inﬁdelity, promiscuity, or ambiguity” [31], a well-
known phenomenon occurring in leukemia. It appears that
the cells retain the phenotype of the original cells but at
the same time deregulate many other pathways characteristic
of other hematopoietic lineages, which could also explain
why there’s expression of fetal hemoglobin chain (HBG1)
together with the adult hemoglobins.
I nc o n c l u s i o n ,i ta p p e a r st h a ta tl e a s tt h em a j o r i t yo f
CML/G0 cells overexpress genes usually associated with
erythro-megakaryocytic developmentwhich is probablycor-
related with the thrombocytosis frequently seen in patients
with CML and also with the spontaneous growth of ery-
throidcoloniesin vitro byCML progenitorsin theabsenceof
erythropoietin, whereas normal progenitors always require
EPO [32].
Figure 2(a) shows the average results of multiple cloning
experiments comparing the cloning eﬃciencies (C.E.s) of
normal and CML total CD34+ cells and the G0 and
G1/S/G2/M subsets. No EPO was added in any of the exper-
iments, but the CML cells consistently produced erythroid
colonies without EPO, often including large or X-large BFU-
E, and sometimes comprising over half of the total colonies,
whereas in the absence of EPO, the normal cells rarely
produced any erythroid colonies and then only tiny or
very small ones. In almost all experiments, the CML G0
cells generated more and larger erythroid colonies than the
G1/S/G2/Mcells.InotherexperimentsnotincludedinFigure
2(a), the addition of EPO to other cytokine combinations
greatlyaugmentedfurthergrowthofCMLerythroidcolonies
as well as stimulating normal ones. It is also evident in
Figure 2(a) that CML total CD34+ and CD34+ G0 cells
producedmoretotalcoloniesthanthecorrespondingnormal
cells when stimulated by the three early acting cytokines KL,
FL, and TPO and to a lesser extend by KL+G− and GM-
CSF, again showing the CML progenitors are more easily
triggered into cycle than the normal cells. However, there
was little diﬀerence or the normal G0 cells had higher total
C.E.s when the cells were near maximally stimulated with 5–
7c y t o k i n e s .
Figures 2(b) and 2(c) show typical experiments com-
paring the cloning results of two normal and two CML G0
cells in more detail. Except for a few tiny or very small
CFU-E, normal G0 cells shown in Figure 2(b) produced
only CFU-GM colonies without EPO and had the greatest
incremental growth of large and extra-large colonies with 5–
7 cytokines; with addition of EPO, about 1/4 to 1/3 of the
normal colonies were erythroid or mixed, some very large.
In marked contrast, the CML G0 cells shown in Figure 2(c),
when stimulated in the absence of EPO by all the single
cytokine and combinations shown (except G-CSF alone and
G-CSF+GM-CSF), produced a mixture of CFU-GM and
CFU-E/BFU-E with about a third to one half of the colonies
being erythroid or mixed and often very large.
The maximum total cloning eﬃciencies of these two G0
samples were ∼14–24%afterstimulationwith 3–7cytokines,
but in other CML and also normal G0 samples total C.E.s of
up to 40–42% were observed after stimulation with multiple
cytokines. No consistent diﬀerences were noted between the
maximum total C.E.s between normal and CML CD34+
cells or G0 or G1/S/G2/M subsets, although there was more
variability in the quality of the CML samples.
3.9. Transcription Factor Expression. Class I Homeobox (Hox)
genes comprise a family of 39 transcription factors that share
a highly conserved DNA binding domain. Since several of
them have been shown to play a role in hematopoiesis [33],
we looked at their expression proﬁle in our microarray.
We found three members of this family under expressed in
CML/G0 cells: HOXB3, HOXA5, and HOXA3.
HOXB3 is expressed in the primitive CD34+ population,
that is, highly enriched for human hematopoietic stem cells
(HSCs), and it is downregulated as the cells diﬀerentiate into
committed progenitors [34], and together with HOXB4 it
is required for normal HSC function. HOXA5 is another
gene involved in hematopoietic lineage commitment and
maturation, and it seems to act as a repressor of the
generationorproliferation oferythroid progenitorcells[34].
Regarding HOXA3, there is not much information about its
function in the hematopoietic system. Taken together, the
pattern of expression of the HOXA genes in our microarray
suggests, again, that the CML CD34+/G0 stem progenitor
cells are more mature than the normal counterpart.
Another two transcription factors are diﬀerentially
expressed in the normal and CML/G0 fractions: NMYC is
under expressed and WT1 overexpressed in CML/G0 cells.
NMYC is a well-known oncogene found to be expressed
in neuroblastomas and retinoblastomas and also in myeloid
and lymphoid leukemias [35], but it has not previously been
reported to be dysregulated in CML. This gene plays a role in
preventing diﬀerentiation so its expression is downregulated
in cells that progress through more mature stages in order to
acquire their ﬁnal phenotype. NMYC is under expressed in
theCML/G0progenitorssoitslevelofexpression maysimply
reﬂect their more advanced diﬀerentiation and more rapid
maturation as previously reported [36].
WT1 pattern of expression in normal HSCS is bipha-
sic: high in quiescent CD34+/CD38−, low in committed
progenitors, and high again in diﬀerentiated cells (CD34−).
WT1 also is not expressed in cells expressing erythroid or
megakaryocyte markers [37]. So, how to explain the higher
expression of WT1 in CML/G0 cells?
It has been reported that the oncogenic signaling from
BCR/ABL can induce WT1 expression [38]a n dt h a tw h i l ei n
normal mice only a few immature cells in the bone marrow
express WT1, when CML is induced the percentage of bone
marrow cells expressing WT1 rises considerably [39]. The
eﬀect of this gene if expressed in progenitors cells is to
keep them in a state in which they are not responsive to
diﬀerentiation inducing signals. So, it could be that while8 Journal of Oncology
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Figure 2: (a) Summary of Multiple Cloning Experiments by normal & CML. Total CD34+ Cells and G0 and G1/S/G2/M fractions.
Comparison of average results of multiple cloning experiments (total n = 47) comparing total cloning eﬃciencies of CML and normal
total CD34+ cells and G0 and G1/S/G2/M subsets with diﬀerent cytokine combinations: KL + FL = TPO n = 8 Experiments; KL + G-CSF
+G M - C S F n = 1 8 ;a n dK L+F L+T P O+G - C S F+G M - C S F± IL-3 ± IL-6 n = 21. (b) Cloning of CD34+ G0 Cells from 2 normal bone
marrow samples. Cloning of 2 normalCD34+ G0 cells enriched from fresh bone marrow samples from 2 normal volunteers using the color
scale of the estimated colony sizes of numbers of cells per colony according to the standard scale described under methods. The CFU-GM
and erythroid (CFU-E/BFU-E) clusters and colonies of all sizes are designated, respectively, CFU-GM and BFU-E on this and subsequent
graphs. C.E. = %total Cloning Eﬃciency. (c) Cloning of 2 CML CD34+ G0 cells enriched from frozen-thawed mononuclear cells obtained
from the peripheral blood of 2 CML patients in chronic phase.
WT1tendstokeeptheCML/G0cellsinanaberrantquiescent
state other programs for diﬀerentiation are still turned on,
such as those inducing diﬀerentiation in the M/E lineages,
another manifestation of lineage inﬁdelity.
3.10. Cancer-Related Genes. As a strategy to identify novel
anticancer treatments speciﬁc for the CML quiescent popu-
lation,we lookedforgenesthat were upregulatedin theCML
fraction and that in the literature had been previously found
to have a potential role in other type of cancers. Following
these criteria, we found three genes: PVT1, ANXA2, and
MARCKS.
MARCKSis a gene important for cell proliferation: it has
been reported that while its expression is low in cell lines
that are actively proliferating its expression increases when
they stop dividing and enter the G0 phase [40]. Additionally,
the over expression of MARCKS inhibits proliferation of
human tumor-derived choroidal melanoma cells [41]. So its
role in CML/G0 cells could be to keep them in an artiﬁcial
quiescent state and as a consequence protect from the action
of cytotoxic drugs. Blocking MARCKS activity would be one
step necessary to make these cells respond again to cytokine
stimuli and make them reenter the cell cycle. MARCKS is a
prominent intracellular substrate of protein kinase C: since10 Journal of Oncology
diﬀerent PKC inhibitors have been developed and available
(like Enzastaurin, LY317615.HCL), this hypothesis could be
tested.
ANXA2 is a lipid- Ca2+-actin binding protein that has
been reported to be upregulated in diﬀerent human tumors
like hepatocellular and pancreatic carcinoma [42]a n da c u t e
promyelocytic leukemia [43]. But while in these type of
tumors it seems to have a positive role in promoting
cancerogenesis and metastasis in other tumors, it seems to
slow down their aggressiveness or tumor cell migration, like
inosteosarcoma andprostatecancer[44].Thediﬀerentfunc-
tional roles of ANXA2 in diﬀerent malignancies probably
reﬂect its tissue speciﬁcity, so without further evidence, it
would be premature to suggest it may have a speciﬁc role in
the CML/G0 population. Nonetheless, it remains a potential
target candidate gene.
The PVT1 gene encodes a number of alternative tran-
scripts, butno proteinorregulatory RNAproductshave been
found so far; recently, it has been suggested that this region
mightencodesfordiﬀerentmiRNASwhereoneatleastseems
to be oncogenic [45]. The ampliﬁcation of this locus has
been shown to contribute to the pathophysiology of ovarian
and breast cancer [46], and over expression of PVT1 has
been detected in a subset of cases of AML [47]a n di no t h e r
myeloid malignancies. PVT1 role in cancer seems to be that
ofan inhibitorofapoptosis, so thisisanotherpotentialtarget
gene that is worth consideration.
These three genes were not identiﬁed as overexpressed in
a previous work that did gene expression proﬁle comparing
total CD34+ CML and normal cells [48], so it is plausible
that the diﬀerent expression levels of these three protein is
due to the fact that they belong to the speciﬁc quiescent
subpopulation of CD34+ CML cells rather than the total
CD34+/CML cells.
3.11. Prominin-1 (CD133). The gene most downregulated in
CML CD34+/G0 cells compared to normal bone marrow
CD34+/G0 cells is prominin-1 or CD133 (–19.6 fold).
Prominin-1 is a pentaspan transmembrane glycoprotein
which was ﬁrst isolated in 1997 from plasma membrane
protrusions on murine neuroepithelial stem cells and was
so named because of its prominent localization in these
protrusions (from Latin, prominere) [49].
There are two isoforms of the gene, AC133-1 and -2
(which is 27 nucleotides shorter): it was demonstrated that
AC133-2 rather than AC133-1 is the predominant transcript
expressed in hematopoietic stem cells (HSCs) derived from
fetal liver, bone marrow, and peripheral blood as well as in
epidermal stem cells, a wide variety of fetal and adult tissues
and several poorly diﬀerentiated human carcinomas, but not
in more diﬀerentiated tumors. Based on these ﬁndings it
was postulated that AC133-2 might serve as a good marker
of undiﬀerentiated cells, including stem and progenitor cells
present in stem cell niches in multiple fetal and adult tissues.
In contrast, the undeleted AC133-1 transcript originally
found in the retinoblastoma cell line was not detectable in
fetal liver or kidney or in adult pancreas, kidney, placenta, or
brain, but was strongly expressed in fetal brain, suggesting
distinct roles for the two isoforms in development and
homeostasis of diﬀerent fetal and mature organs rather than
redundancy. Both CD133 isoforms localize to the plasma
membrane and have been extensively used alone or in
combination with other markers for the identiﬁcation of
stem and progenitor cells from many adult normal tissues
and organs [50] including leukemic stem/progenitor cells
[51].
Most studies have reported CD133 expression is reduced
or lost during later stages of diﬀerentiation, but in a recent
report [52], using a knock-in lacZ reporter mouse model
(Il10
−/−/CD133lacZ) and immunostaining, CD133 expres-
sion was observed in the full spectrum of undiﬀerentiated
and diﬀerentiated colonic epithelial cells in both mice and
humans. Both CD133+ and CD133− metastatic cancer cells
formed colonospheres and tumors in NOD/SCID mice that
could be serially xenotransplanted, and it was noted the
CD133−cellsformedmoreaggressivetumorsandweremore
enriched for phenotypic markers thought to be more typical
ofcancerinitiating cells(CD44+CD24−)thanCD133+cells.
In view of our ﬁnding that CD133 is downregulated in CML
CD34+ G0 cells compared to normal CD34+ G0 cells, it
is of particular interest that the authors suggested that its
downregulation in aggressive colonic cancer may indicate
transformation of primary CD133+ cancer cells into more
malignant CD133− metastatic tumors [52].
3.12.ColocalizationofCD34andCD133Antigens. TheCD34
antigen has been widely used as a marker of human stem
cellsandprogenitorcellsforbothclinicalstemcelltransplan-
tation and laboratory studies characterizing and comparing
normal and leukemic stem and progenitor cells, although
it is recognized that a small subset of CD34− cells also
have repopulating ability and can give rise to CD34+ cells
[53]. Coexpression of CD34 and CD133 has been observed
[53], and the cells expressing both antigens were found to
have a higher cloning potential than those only expressing
CD34 [54]. Numerous studies have led to the recognition
that HSCs are concentrated in the Lin-CD34+CD38−/lo
fraction [55]. Of particular interest, Wagner et al. observed
that the more primitive CD34+CD38− slowly dividing cells
expressed higher levels of CD133 than the fast dividing,
presumably more mature, CD34+ CD38+ cells [56].
3.13. Low Expression of Prominin-1 in CML/G0 Cells May
Contribute to Their Altered Lineage Fidelity and Defective
Control of Homeostatic Cell Density. Unlike normal bone
marrowenriched progenitors which form almost no ery-
throid colonies or only tiny ones in the absence of EPO as
shown in the examples in Figures 2(a), 2(b),a n d2(c),C M L
progenitors often produce erythroid colonies of varying
sizes, some very large, after stimulation with various single
cytokines or combinations of cytokines without EPO. The
production of erythroid colonies by CML progenitors in
the absence of EPO is consistent with the previous ﬁnding
that Bcr-Abl Tyrosine Kinase supports normal erythroid
development in erythropoietin-deﬁcient murine progenitor
cells [57]. Under EPO deprived conditions, we observedJournal of Oncology 11
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Figure 3: Expression of CD133/2 measured by ﬂow cytometry.
Total CD34+ cells, CD34+ G0, and G1/S/G2/M cells enriched from
normal bone marrow, pooled cord blood samples, CML chronic
phase peripheral blood, and ALL-3 cells and stained with antibody
CD133/2 APC (293C3, Miltenyi Biotec). ALL-3 is a p190bcr-abl-
driven growth factor independent cell line derived from the blast
cells in a pleural eﬀusion of a patient with Ph+ ALL.
marked inhibition of CML erythroid colony growth by
several potent inhibitors of Bcr-Abl [25], thus providing
evidence that Bcr-Abl increased Tyrosine Kinase activity
cooperates with KL and other cytokine activated pathways
in early CML progenitors to reprogram and distort their
direction of lineage commitment, which in normal bone
marrow and mobilized peripheral blood progenitors, and
to a lesser extent in cord blood cells, is more dependent
on EPO for production of erythroid cells. The production
of erythroid colonies by CML progenitors without EPO at
ﬁrst appears counterintuitivebecausethemajor expansion in
CML clearly occurs in the granulocyte lineage. However, it is
quite compatible with the upregulation of the genes noted
earlier that are involved in early erythroid development
in CML CD34+ G0 cells compared to normal CD34+ G0
cells.
As already noted, prominin-1 (CD133) is the most
downregulated gene in CML CD34+ G0 cells compared to
normal G0 cells and expression of the CD133/2 antigen is
also low in both CML CD34+ G0 and G1/S/G2/M and Bcr-
Abl driven All-3 cells compared to normal bone marrow
or cord blood CD34+ G0 and G1/S/G2/M cells (Figure 3).
Unlike normal bone marrow or mobilized peripheral blood
CD34+ G0 or G1/S/G2/M cells which form no or only
tiny erythroid clusters on stimulation with 3 to 7 cytokines
without EPO (Figures 2 and 4), we observed that pooled
cord blood G0 and G1/S/G2/M cells often produced small,
medium, and even large erythroid colonies in the absence
of EPO (Figures 4(b) and 4(c)). Figure 4 summarizes a
number of representative experiments comparing the total
cloning eﬃciencies(C.E.s)ofCD34+G0 and G1/S/G2M cells
from normal bone marrow, normal mobilized peripheral
blood, pooled cord blood samples, and chronic phase CML
peripheral blood samples. In all except some of the cord
blood samples, the G0 cells had highertotal C.E.s and almost
always also produced larger GM and erythroid colonies (not
shown) than the G1/S/G2/M cells (Figure 4(a)), providing
additional evidence that they are more primitive.
To further examine the eﬀect of CD133 on direction of
lineage diﬀerentiation, we compared the formation of GM
and erythroid colonies by cord blood CD34+ quiescent and
proliferating CD133+ and CD133- cells. We observed that
cord blood CD34+ G0 133/2+ cells form numerous myeloid
colonies, some very large, but no erythroid colonies when
stimulated by either 3 GFs or 7 GFs w/o EPO (Figure 5(a)).
In contrast, while cord blood CD34+ G0 CD133/2 negative
cells had similar total C.E.s with 7 GFs w/o EPO, they
formed a mixture of myeloid and erythroid colonies with
about a third of the latter being large or extra large. In a
similar experiment shown in Figure 5(b) with pooled cord
blood G0 and G1/S/G2/M cells, again the CD133+ cells
produced only myeloid colonies and CD133+/2 negative
cells from both the quiescent and proliferating fractions
formed many erythroid colonies. The cells derived from the
pooled cordblood samples shown in Figure 5(b) had lower
total C.E.s than those in Figure 5(a), but both the G0 and
G1/S/G2/M CD133/2negative cellshad higher percentagesof
erythroid and mixed colonies, some very large.
Whereas the results clearly demonstrate that CD133/2+
cordblood-derivedG0and G1/S/G2/Mcellsintheabsence of
EPO only form GM colonies and the CD133/2− cells form a
mixture of erythroid and GM colonies, the distinction is less
consistent and the results are more variable in comparable
CML cells. Figure 6(a) illustrates colony formation by CML
G0 and G1/S/G2/M cells with relatively low C.E.s enriched
from pooled samples of two chronic phase CML patients.
Both G0 CD133/2 positive and negative cells formed almost
entirely tiny or small erythroid colonies when stimulated
with7cytokineswhileonlytheCD133/2negativeG1/S/G2/M
cells formed any colonies, again mostly tiny or small
erythroid ones, but with some GM colonies. The three
cytokines,KL+FL+TPO, stimulated growthofvery few or no
colonies. Figure 6(b) shows an example of colony formation
by CD34+ G0 and G1/S/G2/M cells enriched from another
chronic phase CML patient in which the cells formed mostly
GM colonies, but with further separation of G0 CD133/2+
cells, the total C.E. increased by about a third and there were
higher proportions of large and X-large GM colonies and
almost no even very small erythroid clusters. An example of
a third CML cloning experiment is shown in Figure 6(c) in
which chronic phase CML G0 cells had very high total C.E.s
when EPO was added to the 7GFS, especially the CD133+
cells. As usually observed, the G0 cells had higher C.E.s than
the G1/S/G2/M cells. Both the quiescent and proliferating
CD133 negative cells formed mostly erythroid colonies
while the CD133 positive cells formed predominantly GM
colonies even in the presence of EPO, although about 17%
of the colonies were large or X-large BFU-E and mixed
colonies.12 Journal of Oncology
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Figure 4: Comparing the total cloningeﬃciencies (C.E.s) of CD34+ G0 and G1/S/G2M cells from normal bone marrow, normal mobilized
peripheralblood,pooledcordbloodsamples,andchronicphaseCMLperipheralbloodsamples.TotalCloningEﬃciencies(CFU-GM+CFU-
E/BFU-E) at14-15daysofnormalandCMLCD34+ G0andG1/S/G2/M cells afternear-maximalstimulationwith5–7cytokines,allwithout
EPO:(a)CD34+G0andG1/S/G2/Scellsfrom3normalbonemarrowsamples,2normalmobilizedperipheralbloodsamples,5pooled Cord
Blood samples, and 10 CML peripheral blood samples. The values for the cord blood CD133+ and CD133- bars shown are the average of 3
separate pooled cord blood experiments. (b) The same CD34+ G0 only samples showing proportions of myeloid (CFU-GM) and erythroid
(CFU-E+BFU-E) colonies.(c) The same as B but CD34+ G1S/G2/M cells.
In summary, based on our observations so far, it appears
that Prominin-1, the product of the gene most downregu-
lated in CML CD34+ G0 cells, is also underexpressed on the
surface of both CML CD34+ G0 and G1/S/G2/M compared
to normal bone marrow or cord blood CD34+ G0 and
G1/S/G2/M cells (Figure 3). Cord blood CD34+ G0 133/2
positive cells form numerous myeloid colonies, some very
large, but no erythroid colonies when stimulated by either
3G F so r7G F sw i t h o u tE P O( F i g u r e s5(a) and 5(b)). In
contrast, under the same conditions, cord blood CD34+ G0
CD133/2 negative cells form a mixture of myeloid and ery-
throid colonieswith some ofthe latterbeing large or X-large.Journal of Oncology 13
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Figure 5: (a) CFU-GM and CFU-E/BFU-E colony formation by CD34+ G0 CD133/2 positive and negative cells, enriched from 3 pooled
cord blood samples when stimulated by KL+FL+TPO and the same GFs + G-CSF+GM-CSF + IL-3 + IL-6. No EPO was added. C.E. = %
total cloning eﬃciency. (b) Comparison of three pooled cord blood CD34+ G0 and G1/S/G2/M CD133/2 positive and CD133/2 negative
cells ability to form CFU-GM and CFU-E/BFU-E when stimulated by the same 3 or 7 cytokines without EPO as in Figure 5(a).T h et o t a l
C.E.s of the enriched G0 and G1/S/G2/M cells from these pooled cord blood samples are lower than those in Figure 5(a), but again only the
CD133/2 negative cells of both the G0 and G1/S/G2/M fractions formed erythroid colonies.
The role of (downregulated) CD133 in CML CD34+
G0 and G1/S/G2/M cells is presently less clear and appears
to be more complex. The CML G0 cells in Figure 6(a)
had low C.E.s and both the CD133 positive and negative
fractions produced almost entirely tiny and small erythroid
colonies even when stimulated by 7 cytokines, while only
theG1/S/G2/MCD133−cellsproducedasubstantialnumber
of colonies, mostly erythroid. In the experiment shown in
Figure 6(b), the CML G0 CD133+ fraction when stimulated
with the same 7 GFs without EPO increased the total C.E.
by about a third compared to the total G0 cells, but the
colonies were almost entirely GM, whereas the total G0 cells
produced about 10% small- and medium-sized erythroid
colonies. Finally as shown in Figure 6(c), the CML CD133+14 Journal of Oncology
Cloning of CML CD34+ and Gl/S/G2/M cells and CD133/2 Pos
and CD133/2 Neg subfractions stimulated by 3or7 cytokines
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Figure 6: Continued.Journal of Oncology 15
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Figure 6: (a) Cloning of CD34+ G0 and G1/S/G2/M cells enriched from pooled peripheral blood samples of 2 untreated chronic phase
CML. The total C.E.s were low, and almost all of both the GM and erythroid colonies were tiny, small, or medium sized with very few large
colonies and with very few or no colonies after stimulation with 3 growth factors (KL+FL+TPO), pointing out the variable quality of the
CML samples received. In this case, both the G0 CD133 positive and negative fractions formed almost entirely small erythroid clusters and
colonies with 7GFs, but only the CD133 negative G1/S/G2/M cells produced colonies, including some GM colonies. (b) Colony formation
by G0 and G1/S/G2/M cells enriched from the peripheral blood of a chronic phase CML patient. The sample produced GM colonies with
fairly high C.E.s following stimulation with 3 or 7 cytokines without EPO. With additional enrichment of the G0 cells (G0 CD133/2+) the
C.E.s further increased by about a third, with production of almost entirely GM colonies. (c) Maximum stimulation of G0 and G1/S/G2/M
cells enriched from the peripheral blood ofa chronic phaseCML patient.The G0 cells had a high total C.E. after stimulationwith 8 cytokines
shown, including EPO. Even with addition of EPO, while both the G0 and G1/S/G2/M CD133 negative cells produced predominately large,
X-large erythroid, and mixed colonies, the CD133 positive fractions produced mainly GM colonies, but also about 20% large and X-large
BFU-E plus mixed colonies.
G0 cells when stimulated by 7 GFs + EPO had one of the
highest C.E.s (47.25%) we have observed with mostly large
and X-large GM colonies, but also about 17% large and X-
large BFU-E and mixed colonies, while the CD133− cells
formed mostly erythroid colonies, mostly large or X-large.
The aboveobservationssuggest thatexpression ofCD133
in both normal and CML progenitors favors GM diﬀeren-
tiation while CD133 negative cells produce a mixture of
erythroid and GM colonies. However, the precise function
of CD133 is still very uncertain and confounded by the
necessity to use multiple cytokines to stimulate growth.
CML and cord blood progenitors are less dependent on
EPO in producing erythroid cells than normal bone marrow
progenitors, but addition of EPO markedly shifts the cells
toward erythroid diﬀerentiation. Overall, the results suggest
that Prominin-1 may have an important role in determining
the direction of lineage commitment, especially in cord
blood and CML progenitors. We found no consistent
diﬀerence in the numbers or sizes of the colonies produced
by either normal or CML quiescent or proliferating CD133+
or CD133− cells, although some experiments suggested
enrichment of one or the other might further enhance their
overall proliferative potential.
3.14. Correlations of Gene Expression and Surface Antigen
Expression. An attempt was made to see if it was possible
to correlate changes in gene and surface antigen expression
as measured by ﬂow cytometry in subpopulations of normal
and CML cells, but because of the small number of cells
usually recovered it was only possible to do limited surface
phenotyping in a minority of enriched samples.16 Journal of Oncology
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Figure 7: (a) Expression of surface antigens determined by ﬂow cytometry of normal mononuclear cells (MNCs) after Ficoll Hypaque
separation from a normal frozen-thawed mobilized peripheral blood sample compared to expression of total CD34 cells after two
enrichments of the same MNCs on Miltenyi columns as described in Methods. Insuﬃcient numbers of CD34+ cells were recovered to
permit comparison of additional antigens. (b) Changes in cell surface antigen expression in total CD34+ cells enriched from a sample of
frozen thawed mononuclearcells from normalmobilized peripheral blood during 12 days of culture. The cells were stimulated to proliferate
with the two combinations of cytokines shown in the concentrations stated under Methods.Journal of Oncology 17
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Figure 8: Continued.18 Journal of Oncology
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Figure 8: (a) Comparative cell surface antigen expression of 3 normal total CD34+ and CD34+ G0 cells enriched from 2 fresh normal
bone marrow samplesand onefrozen-thawed normalmobilized peripheral blood (MPB) sample.(b) Comparative expression ofcell surface
antigens of 3 CML total CD34+ and CD34+ G0 cells enriched from 3 frozen-thawed mononuclear cell fractions enriched from peripheral
blood samples from 3 CML patients. The sample in the upper chart was from a patient in early accelerated phase, while the lower 2 were
from patents in chronic phase.Journal of Oncology 19
4) Antigens consistently low in total CD34+ cells and even lower in CD34+ G0 cells: CD13,
14, 15 usually < 10% in total CD34+ cells and still lower in CD34+ G0 cells; CD3, CD19
usually < 5% in total CD34+ cells and still lower in CD34+ G0 cells
Similarities and diﬀerences in cell surface antigens between
normal and CML enriched total CD34+ cells and CD34+ G0 cells
1) CD34 is consistently positive in all normal and CML total CD34+ populations (96–100%)
2) No consistent diﬀerences were noted between any of the normal and CML subsets, except
the CML CD34+ G0 cells sometimes had lower expression of HLA-DR (60–95%) and usually
of CD38 (25–40%) than normal BM CD34+ G0 cells (90–98% and 65–90% respectively)
3) Variable, but usually antigens moderately to substantially lower in CD34+ G0 cells than in
total CD34+ cells: CD33, CD38, CD36, glycophorin A, CD41, CD61, CD71, CD45RA
5) Antigens with no consistent diﬀerences between total CD34+ and CD34+/G0 cells:
CD90, CD117 highly variable (∼ 10–60% Pos) in both populations; sometimes higher,
sometimes lower in G0 than in total CD34+ cells
6) CD34, CD38, CD90, glycophorin A, and CD45RA expression declines rapidly, and CD14,
CD15, CD36, and CD41 increase when total CD34+ or CD34+ G0 cells are stimulated to
divide in liquid culture; CD33 and other antigens show less change
Figure 9: Summary of the most consistent similarities and diﬀerences observed in cell surface antigen expression in multiple experiments
between normal and CML enriched total CD34+ and CD34+ G0 cells.
Examples of representative experiments showing simi-
larities and diﬀerences in expression of surface antigens are
s h o w ni nF i g u r e s7 and 8, and a summary of the overall
results of multiple surface phenotyping experiments is given
in Figure 9.
In these and otherstudies, there were insuﬃcient CD34+
total cells or subsets to compare additional surface antigens
other than those shown. As illustrated in Figure 1(a) and
Table 1, the CD34+ G1/S/G2/M cells are usually much more
numerous than the CD34+ G0 cells so their phenotype is
very similar to that of the total CD34+ cells (not shown).
Figure 7(a) shows a typical study comparing surface markers
of normal mononuclear cells from mobilized peripheral
bloodandtheenrichedtotalCD34+cellsfromthesamesam-
ple showing marked enrichment of CD34+cells and reduced
expression of antigens expressed on more diﬀerentiatedcells,
including CD14, CD45RA, CD90, CD3, and CD19. Figures
8(a) and 8(b) show comparisons of cell surface antigen
expression of normal and CML total CD34+ and CD34+/G0
cells in several typical experiments. As would be expected,
in most but not all normal and CML samples, expression
of CD33, CD38, and CD45RA were reduced in the CD34+
G0 cells compared to the total CD34+ cells. Figure 7(b)
shows the changes that occur in surface antigens during
12 days in liquid culture when normal CD34+ cells are
stimulated to proliferate by two combinationsof 4 cytokines.
In the latter experiment, following stimulation with both
cytokinecombinations, CD34,CD38,GlycophorinA, CD90,
and CD45 RA expression rapidly declined and this usually
occurred even faster in stimulated CML CD34+ cells (not
shown). Most surface markers associated with granulo-
cyte/macrophage, erythrocyte or megakaryocyte diﬀerentia-
tion increased both in normal and CML CD34+ cells (e.g.,
CD 14, 15, 36, 41), although CD61 declined slightly. As is
evident from comparing individual experiments, there was
considerable variation in both normal and CML individual
samples, but we have nevertheless attempted to provide an
overall summary in Figure 9 of the most consistent ﬁndings
in multiple experiments of the similarities and diﬀerences
in surface antigen expression between normal and CML
total CD34+ cells and CD34+ G0 cells and when the latter
are stimulated to proliferate. Overall, we did not detect
any consistent diﬀerences between normal and CML total
CD34+ cells or in their G0 and G1/S/G2/M subsets except
that the CML G0 cells usually had lower percentages of
cells expressing CD38 and sometimes of HLA-DR than the
normal G0 cells, but the results were not consistent enough
to draw any ﬁrm conclusions.
4.Discussion
This study was initiated based on the assumption that
quiescent CML cells and early progenitor cells may diﬀer in
their pattern of gene expression from comparable normal
cells and that if critical diﬀerences could be identiﬁed, they
would help to reveal the underlying molecular mechanisms
responsible for the excessive overproduction of the CML
population. It was further hoped that some vulnerable
diﬀerences would be discovered that would be susceptible to
targeting by highly selective drugs, since it was assumed that
the quiescent cells would be largely unaﬀected by existing
BCR-ABL inhibitors such as Imatinib and Dasatinib as well
as other drugs active against proliferating cells. So far, there
has been only one other study attempting this [58], which
was performed using the same methods but using fewer
samples (ﬁveCMLandtwo normal)and an oldermicroarray
platform with considerably less genes represented (14,500
versus 38,500).
Because at least 105 cells were required for each sample
for microarray analysis and the enriched CD34+ G0 cells
comprised less than 0.02% of the starting cell populations,
it was diﬃcult to obtain suﬃcient cells, especially patient
samples, to carry out the study. We initially collected
10 CML samples, but 2 had insuﬃcient RNA so only 8
are included. We also performed microarray analyses on20 Journal of Oncology
Table 2: List of genes, discussed in the paper, with signiﬁcantly
diﬀerential gene expression in CML CD34+/G0 cells compared to
normal bone marrow. The fold change is linear and positive values
mean genes more expressed in CML and negative values vice versa.
In the case that for one gene there is more than one set of probes
signiﬁcantly diﬀerentially expressed, we reported the highest value
among them. For the complete list of genes, see Supplementary
Material available online at doi:10.1155/2011/798592.
Gene symbol
Fold
change
(CML/BM)
Gene symbol
Fold
change
(CML/BM)
Apoptosis HLA-E −2.81
FAS +2.9 HOXA3 −4.44
MX1 −3 HOXB6 −4.97
BIRC3 −3.1 SPINK2 −10.71
MALT1 −4.44 NRIP1 −2.41
NALP1 −2.29 PRKCH −6.43
Cell proliferation RAPGEF2 −2.6
MTSS1 +5.58 TLOC1 −1.77
DLG7 +3.71 HES-1 −8.45
ANLN +3.56 Diﬀerentiation
CCNB2 +3.34 CD36 +19.7
CDC6 +3.28 XK +8.7
CETN3 +3.16 Klf1 +6.97
MAP9 −3.51 ITGA2B (CD41) +6.51
MAP9 −3.51 GATA1 +4.0
CDC14B −5.18 NFE2 +3.3
DNA replication TESC +4.5
RRM2 +5.57 ANK1 +3.9
GINS1 +3.49 HBQ1 +3.2
TOPO2A +3.34 HBD +18.4
GINS2 +3.33 HBG1 +17.3
Growth
factors/cytokines
HBB +13.4
IL7 +3.26 NCF4 +3.9
Stem cell markers BCL6 −4.88
PROM1 −19.75 GATA3 −4.99
HLF −18.08 TFR2 +5.5
GBP2 −3.85 LEPR +20.6
FLT3 −6.6
∗SMAD7 −8.7
SPTBN1 −4.97
∗NMYC −4.1
RBPMS −5.93 Transcription factors
GATA3 −4.99 HOXB3 −3.23
MPL (CD110) −6.11 HOXA5 −3.76
TNFSF10 (TRAIL) −3.07 WT1 +3.7
MSI2 −4.18 Cancer genes
ID1 −7.32 PVT1 +7.0
ARG2 −2.92 ANXA2 +5.75
BIRC3 −3.88 MARCKS +8.21
CRHBP −14.75
CD34+ G0 and G1/S/G2/M cells enriched from cord blood
and normal G-CSF mobilized peripheral blood samples,
but excluded them from the ﬁnal analysis because some of
the results diﬀered from cells enriched from normal bone
marrow samples and we considered the latter to be more
appropriate normal controls. Both the normal and CML
quiescent and proliferating fractions consisted of 96–100%
CD34+ primitive blast cells and less than 1% of CD34+ G0
cellsincorporatedBrdU,so almost all ofthe latterwere either
in G0 or early G1. Because there are no deﬁnitive markers
to distinguish stem cells from early progenitor cells, it is
unknown what percentage of each was present in the CD34+
G0 fractions, but we presume the majority of cells in both
the normal and CML fractions were progenitors in various
stages of development. Ideally, we would have preferred to
also compare normal and CML stem cells, but were unable
to do this because of a lack of clear stem cell markers and
insuﬃcient cell numbers.
Some of the genes that were diﬀerentially expressed in
normal and CML/G0 cells revealed a number of interesting
ﬁndings which correlate nicely with some of the biological
and functional abnormalities previously observed in CML
cells. These ﬁndings include the following. (i) In keeping
with the gene expression data, normal and CML quiescent
G0 cells are more highly enriched in primitive cells than
the proliferating G1/S/G2/M cells. (ii) The CML G0 cells
are in a slightly more advanced stage of development
than the normal G0 cells, and as previously reported
by Graham et al. [58], the CML CD34+ G0 cells are
more similar to the CD34+ proliferating cells than are
the normal G0 and G1/S/G2/M fractions. (iii) In keeping
with their more advanced stage of development and their
upregulation of genes involved in DNA replication or part
of the mitotic spindle machinery, CML/G0 cells are more
poised to begin proliferating than normal G0 cells and are
more sensitive to growth stimulation by single cytokines
or combinations known to act on early progenitors and
stem cells. While normal and CML/G0 cells are almost
equally responsive to stimulation by multiple cytokines, the
CML cells are triggered into cycle more rapidly. (iv) Once
CML quiescent progenitors are stimulated by cytokines to
begin proliferating, they undergo further diﬀerentiation and
maturationmore rapidly thannormal quiescentprogenitors,
but both granulopoiesis and erythropoiesis are usually less
eﬃcient than in normal hematopoiesis as shown in cloning
experiments in which the CML cells form many more
small CFU-GM, CFU-E, and BFU-E compared to normal
progenitors [14, 32]. (v) Whereas normal CD34+ cells form
almost entirely granulocyte/monocyte clusters and colonies
in clonogenic experiments when stimulated by cytokines
in the absence of erythropoietin, CML CD34+ G0 cells
consistently spontaneously form a combination of GM
and erythroid colonies in the absence of EPO. The gene
expressiondataclearlyshowsthatCML/G0cellshavemarked
overexpression of genes associated with development of the
erythrocyte and megakaryocyte lineages, and Graham et al.
noted similar ﬁndings [58]. (vi) Prominin-1 (CD133) is the
genemostdownregulatedinCMLG0cells,andthereislower
expression ofCD133onthesurface ofthesecells. CordbloodJournal of Oncology 21
G0CD133+cellsformonlyGM colonieswithoutEPO while
CD133− cells form a mixture of GM and erythroid colonies.
The downregulation of CD133 appears to be associated
with the spontaneous formation of erythroid colonies by
CML progenitors in the absence of EPO, but its precise
role remains to be better clariﬁed. It has been known for
many years that both normal and neoplastic cell populations
contain signiﬁcant numbers of “resting” or quiescent cells
that are considerably less sensitive to the damaging eﬀects
of irradiation, cytotoxic drugs, and other injurious agents
than are proliferating cells [59, 60]. The dormant state
is a protective mechanism that is of crucial importance
in enhancing a population’s probability of survival under
adverse conditions, and early on the concept that dormant
cancer cells are important obstacles to curability was widely
recognized by both basic and clinical scientists [15, 25, 61].
If one accepts the premises that almost all lethal cancers
originate in adult stem cells or early progenitors functioning
as stem cells, that these cells are essential for initiation,
maintenance, and expansion of the cancers, and that a large
fraction of these cells, like normal stem cells, reside in a
quiescent state in which they are resistant to most therapies,
then it is obviously important to better understand their
derivation and properties, to determine how normal and
cancerquiescentstemcellsmay diﬀer,andtolookforwaysto
developspeciﬁc targetedtherapiesbasedonthesediﬀerences.
Activation of quiescent cells following a mitogenic
stimulus by serum, cytokines, or other factors is highly
complex and involves the coordinated and selective induc-
tion of expression and repression of hundreds of genes
including speciﬁc cyclins, cyclin-dependent kinases (CDKs),
and protein kinase inhibitors (PKIs). Many cell cycle genes
aretranscriptionally silentinquiescentcells,andtheyexpress
only a limited number of cytokine receptors, and recent
studies have shown that siRNAs and microRNAs are also
involved in repressing gene transcription and translation in
quiescent cells. When one considers the staggering complex-
ity of all of the cytokines and other regulatory factors and
cellularinteractionsthat determinewhethera quiescentstem
cell residing in its protected niche is going to divide while
simultaneously deciding what kinds of cells to produce, it
is hardly surprising that our present understanding of the
mechanisms regulatingstemcellbehaviorisveryincomplete.
In our analysis, it appears that in many cases, clusters of
presumably related genes that are diﬀerentially expressed
are all associated with a particular stage of development or
function, suggesting that their common dysfunction in CML
G0 cells may involve aberrant co-regulation.
MostauthoritiesagreethattheHSCpopulationishetero-
geneous, but it is still uncertain at what level of development
the system permits changes to occur in phenotype and
functionality, or when the diﬀerentiation hierarchy becomes
ﬁxed.Circumstantial evidenceforboth normal andleukemic
stem cells favors a heterogenic model in which there is a
continuum of stem and early progenitor cells with grad-
ually declining potentials for self-replication, pluripotency,
and other stem cell properties, but that some cells may
also exhibit ﬂexibility in responding to diﬀerent stochastic
inﬂuences in their developmental milieus. Some degree of
reversibility may also exist whereby early progenitors can
retain or reassume more primitive stem cell properties if
needed, such as the ability for more extensive self-replication
in order to replace or supplement damaged stem cells. How-
ever, it is likely that signiﬁcant reversibility is restricted to
early progenitorsand thatoncetheyhavebecomecommitted
to diﬀerentiate along a particular lineage, it is doubtful that
they can revert to functioning as stem cells. With regard
to cancer stem cells, some years ago we postulated that
most leukemias originate in “limited stem cells” which have
more limited pluripotency than normal primitive HSCs, but
retain suﬃcient self-replicating potential to initiate a lethal
leukemia[11].Manycurrentresearchersnowagree,although
some prefer to call them leukemia or cancer “initiating cells”
to distinguish them from true HSCs.
While cells undergoing diﬀerentiation and maturation
can become temporarily arrested or slowed in their progres-
sion through other phases of the cell cycle under certain
conditions (e.g., hypoxia, increased cell density, exposure
to toxins, cytotoxic drugs, irradiation, or other damaging
agents), itisusually only stemcellsand primitive progenitors
that remain in a quiescent state for extended periods under
normal steady-state conditions. Once progenitors become
ﬁrmly committed to diﬀerentiation and maturation, serial
cloning studies conducted in vitro [32] and cytokinetic
labeling studies with 3H-thymidine conducted in vivo [24,
62] have shown that both normal and leukemic cells usually
proceed to undergo a variable but limited number of
maturation divisions to produce terminally diﬀerentiated
cells (which may be highly abnormal in leukemia and
other malignancies), and which are incapable of reverting
to regain signiﬁcant self-renewal or other essential stem cell
properties. While our in vivo 3H-thymidine labeling studies
were less extensive in patients with lymphomas or solid
tumors growing in ascetic form [63, 64], in cases in which it
was possible to distinguish neoplastic cells in diﬀering states
of maturity, it appears that once the neoplasticcells become
committed to maturation, if the environment is suitable,
they usually continue to divide but are only capable of a
limited number of divisions before dying spontaneously and
are incapable of reproducing the disease. Overall, our in vivo
labeling studies strongly suggest that the number of dormant
cancer stem and progenitor cells continue to increase as
the population of cancer cells expands and that they, thus,
constitute a progressively greater obstacle to curative therapy
in many types of cancer [11, 25, 65].
The constitutive tyrosine kinase activity of the p210bcr-abl
protein causes abnormal phosphorylation of regulatory
proteins in numerous interacting signaling pathways [3,
25, 66, 67]. The overall signaling networks altered by Bcr-
Abl are highly complex [68], indeed reaching a level of
complexity that some observers have likened to Heisenberg’s
uncertainty principle in quantum mechanics. Nevertheless,
although the speciﬁc signaling changes responsible for each
of the biological abnormalities that have been described are
still incompletely deﬁned, it is highly likely that the faulty
signaling disrupts multiple interactive networks that nor-
mally tightly regulate the orderly well-coordinated processes
of proliferation, diﬀerentiation, and maturation in normal22 Journal of Oncology
hematopoiesis. This misregulation can probably explain all
the abnormalities observed in early-stage CML including the
initial overproduction of GM progenitors, the imbalanced
lineage apportionment, the ineﬃciency of production of
both granulocytes and erythrocytes, and all the other more
subtledysplastic morphological,biochemical,and functional
changes that have been described [25].
Gleevec and some of the newer Bcr-Abl inhibitors are
highly eﬀective in globally inhibiting the increased tyrosine
phosphorylation of multiple proteins involved in these
signaling pathways [25, 69–71] and since Bcr-Abl is usually
the sole mutation in early stage CML, the progenitors
are restored to near normal behavior when the kinase
is adequately inhibited. At higher concentrations, the Abl
TKI inhibitors are lethal to both fresh primary CML
progenitors and Bcr-Abl-driven cell lines while at still higher
concentrations, they also kill normal progenitors and cell
lines not driven by Bcr-Abl, the exact normal: CML lethal
concentration ratios depending on the particular cells and
inhibitors.
However, as suggested by the usual relatively slow induc-
tion of remissions in CML patients over the course of weeks
or months, it is doubtful if the BCR-ABL inhibitors when
administered in clinically tolerable doses actually kill many
of the proliferating CML progenitors and precursors. Rather,
by inhibiting Bcr-Abl’s constitutive tyrosine kinase activity,
they at least transiently restore the cells to functioning
more normally, and in so doing the CML progenitors
cease excessive cell production, presumably by reacquiring
the ability to respond properly to quorum sensing signals
that ensure maintenance of normal homeostatic cell density
limits. Meanwhile, the later CML progenitors which are
already committed to diﬀerentiation continue to proceed
through a limited number of maturation divisions and then
die as terminally diﬀerentiated cells, just as do normal cells.
After the body burden of leukemic cells has been suﬃciently
reduced, the residual normal stem cells are released from
the CML cells’ (poorly understood) inhibitory eﬀects and
resume production, usually resulting in a complete hema-
tologic or cytogenetic remission. The BCR-ABL inhibitors
are clearly a very important advance since they are able to
induce durable remissions in the majority of CML patients
in chronic phase, butthey are not usually curativesince most
patients relapse if therapy is discontinued, probably because
quiescent CML stem/progenitor cells are not killed by the
drugs and are able to reproduce the disease [9, 72]. Several
mechanisms of resistance have also been well described as
noted earlier [7, 8]
Thus, while Gleevec and other Bcr-Abl TKIs are very
eﬀective in the early stage of CML in largely eliminating
the majority of proliferating Ph+ progenitor and precursor
cells, more attention should be given to seeking ways to
selectively kill the quiescent leukemia stem and progenitor
cells. While our own studies so far have not revealed any
speciﬁc vulnerable targets, it is important that the search be
continued. The alterations in gene expression described here
must be conﬁrmed in a larger number of patients, and if
possible with further technological advances, in still more
highly enriched populations of early progenitors and stem
cells. As the search proceeds, the signiﬁcance of some of the
diﬀerences in gene expression reported here may become
clearer and eventually lead to discovery of new ways to
selectively kill the quiescent CML stem and progenitor cells.
For a number of reasons, it has become increasingly diﬃcult
to obtain large enough samples of CML cells to carry out the
rigorous procedures required to isolate suﬃcient numbers of
highly enriched stem and progenitor cells for further studies,
so this is another important issue that must be addressed.
In a broader sense, it is perhaps even more important to
designsimilartherapeuticstrategiesforothertypesofcancer.
Much of the recent development of anticancer drugs has
been directed towards producing diﬀerent classes of drugs
that block segments of one or more signaling pathways that
are known to be dysregulated by the particular initiating
mutation(s) commonly found in diﬀerent types of cancer.
However in advanced malignancies it is often diﬃcult
to distinguish the importance of the primary causative
mutation(s) compared to that of secondary or still later
(passenger) mutations and the situation may become further
complicated by multiple epigenetic changes. A huge number
of new drugs of diﬀerent classes are now available, but few
cause complete or durable remissions and they are almost
never curative. Greater emphasis should therefore be placed
on more clearly identifying and whenever possible selectively
targeting the primary driving mutations in the cancer stem
or early progenitor cells in early stage disease, and also in
developing new strategies to selectively kill the quiescent
stem or progenitor cells that escape most current therapies.
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